Daratumumab after allogeneic hematopoietic cell transplantation for multiple myeloma is safe and synergies with pre-existing chronic graft versus host disease. A retrospective study from the CMWP EBMT
Vincent, Laure; Gras, Luuk; Ceballos, Patrice; Finke, Jürgen; Passweg, Jakob; Harel, Stéphanie; Rosinol, Laura; Minnema, Monique; Teipel, Raphael; van Doesum, Jaap; Hänel, Mathias; Lenain, Pascal; Botella-Garcia, Carmen; Koenecke, Christian; Ducastelle, Sophie; Sanz, Jaime; Schroyens, Wilfried; Zuckerman, Tsila; Monaco, Federico; Koster, Linda; de Wreede, Liesbeth; Hayden, Patrick J; Schönland, Stefan; Yakoub-Agha, Ibrahim; Beksac, Meral
(2022) Bone Marrow Transplantation, volume 57, issue 3, pp. 499 - 501
(Letter)
Download/Full Text
The full text of this publication is not available.
Keywords: Transplantation, Hematology, Letter
ISSN: 0268-3369
Publisher: Nature Publishing Group
Note: Funding Information: We are grateful for all participating centers: Xavier Poiré, Cliniques Universitaires St. Luc, Brussels, Belgium; Nicolaas Schaap, Nijmegen Medical Center, Nijmegen, Netherlands; Jenny Byrne, Nottingham University, Nottingham, UK; Gandhi Damaj, CHU CAEN, Caen, France; Dries Deeren, AZ Delta, Roeselare, Belgium; Manos Nikolousis, Birmingham Heartlands Hospital, Birmingham, UK; Domenico Russo, USD Trapianti di Midollo, Adulti, Brescia, Italy; Joan Hendrik Veelken, Leiden University Hospital, Leiden, Netherlands; Claude Eric Bulabois, CHU Grenoble Alpes - Université Grenoble Alpes, Grenoble, France; Yves Chalandon, Département d’Oncologie, Service d’Hématologie, Geneva, Switzerland; Manuel Jurado Chacón, Hospital Univ. Virgen de las Nieves, Granada, Spain; Sonja Martin, Robert Bosch Krankenhaus, Stuttgart, Germany; Josep Maria Ribera Santasusana, ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Spain; Simona Sica, Universita Cattolica S. Cuore, Rome, Italy.
(Peer reviewed)